Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study.

about

Apatinib as targeted therapy for sarcoma.

P2860

Q54977588-89909A3B-00CB-4D04-B04F-CE98A92E8277

P2860

Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study.

Item

http://www.wikidata.org/entity/Q48563213

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Efficacy and safety of apatini ...... rcoma: An observational study.

@en

Efficacy and safety of apatini ...... rcoma: An observational study.

@nl

type

Item

label

Efficacy and safety of apatini ...... rcoma: An observational study.

@en

Efficacy and safety of apatini ...... rcoma: An observational study.

@nl

prefLabel

Efficacy and safety of apatini ...... rcoma: An observational study.

@en

Efficacy and safety of apatini ...... rcoma: An observational study.

@nl

P1476

Efficacy and safety of apatini ...... rcoma: An observational study.

@en

P2093

Baorang Zhu

http://www.w3.org/2001/XMLSchema#string

Jing Li

http://www.w3.org/2001/XMLSchema#string

Liyan Diao

http://www.w3.org/2001/XMLSchema#string

Lvhua Gai

http://www.w3.org/2001/XMLSchema#string

Qiaosheng Xie

http://www.w3.org/2001/XMLSchema#string

Wuwei Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis.

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.

Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series

Successful treatment of advanced malignant fibrous histiocytoma of the right forearm with apatinib: a case report

Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.

Opportunities for improving the therapeutic ratio for patients with sarcoma.

P304

198-204

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/15384047.2017.1416275

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29261005

http://www.w3.org/2001/XMLSchema#string

P932

5790336

http://www.w3.org/2001/XMLSchema#string

Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study.

about

P2860

P2860

Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932